The Alzheimer’s drug being tested by Penn Medicine has been approved by the Food and Drug Administration
Campus Penn Medicine on October 3, 2020. Credit: Max Meester The Federal Drug Administration recently approved a drug being trialled by the Penn Memory Center to reduce the risk of Alzheimer’s disease. The medicine, Leqembi, earned FDA approval Under Expedited approval process On January 6, a trial after AHEAD evaluated its effectiveness on volunteers is … Read more